Last reviewed · How we verify
Cannabidiol Oral Product
Cannabidiol (CBD) is a non-intoxicating cannabinoid that modulates multiple molecular targets including serotonin receptors, TRPV1 channels, and endocannabinoid signaling to produce anti-inflammatory, anxiolytic, and anticonvulsant effects.
Cannabidiol (CBD) is a non-intoxicating cannabinoid that modulates multiple molecular targets including serotonin receptors, TRPV1 channels, and endocannabinoid signaling to produce anti-inflammatory, anxiolytic, and anticonvulsant effects. Used for Seizures associated with Lennox-Gastaut syndrome, Seizures associated with Dravet syndrome, Seizures associated with tuberous sclerosis complex.
At a glance
| Generic name | Cannabidiol Oral Product |
|---|---|
| Sponsor | University of Connecticut |
| Drug class | Cannabinoid |
| Target | Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Immunology |
| Phase | FDA-approved |
Mechanism of action
CBD does not directly bind with high affinity to CB1 or CB2 receptors but instead acts as an allosteric modulator of these receptors and interacts with serotonin 5-HT1A receptors, vanilloid TRPV1 channels, and other ion channels. This multi-target mechanism underlies its therapeutic effects in reducing seizure frequency, anxiety, and inflammation without producing the psychoactive effects associated with THC.
Approved indications
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
Common side effects
- Somnolence
- Diarrhea
- Fatigue
- Decreased appetite
- Elevated liver transaminases
- Rash
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures (PHASE1)
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study (PHASE1)
- Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI (PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Cannabidiol for Reduction of Brain Neuroinflammation (PHASE2)
- A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol Oral Product CI brief — competitive landscape report
- Cannabidiol Oral Product updates RSS · CI watch RSS
- University of Connecticut portfolio CI